Ingram John R, Lambert Jérémy, Ciaravino Valerie, Rolleri Robert, Pansar Ingrid, Peterson Luke, Pelligra Christopher G, Thorlacius Linnea
Division of Infection and Immunity, Department of Dermatology & Academic Wound Healing, Cardiff University, Cardiff, UK.
European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.
Dermatol Ther (Heidelb). 2025 May;15(5):1093-1111. doi: 10.1007/s13555-025-01346-w. Epub 2025 Mar 28.
Hidradenitis suppurativa (HS) is a chronic inflammatory disease characterised by painful skin lesions which negatively impact patients' physical and mental wellbeing. The HS Symptom Daily Diary (HSSDD) and HS Symptom Questionnaire (HSSQ) are patient-reported outcome (PRO) tools capturing patient-perceived severity of HS symptoms. Here, we report the psychometric properties of HSSDD and HSSQ along with score interpretation thresholds.
Pooled data from patients with moderate to severe HS in two phase 3 studies (BE HEARD I II) were analysed. Test-retest reliability was evaluated using intraclass correlation coefficients (ICCs). Convergent validity was assessed between the HSSDD (N = 934) and HSSQ (N = 1007) compared with relevant PROs and clinician-reported outcomes (ClinROs) at baseline and Week (Wk)16. Known-groups validity was assessed, comparing HSSDD and HSSQ scores between participant subgroups pre-defined using PRO/ClinRO measures (Patient Global Impression [PGI] of HS severity, Hurley stage, International HS Severity Score System). Responsiveness was evaluated by correlating changes from baseline to Wk16 in HSSDD and HSSQ scores with changes in PGI scales. Clinically meaningful within-patient improvement thresholds were estimated using anchor- and distribution-based analyses. Symptom/impact severity thresholds were estimated using receiver operating characteristic curve analyses.
At Wk16, HSSDD and HSSQ completion rates were 70.1% and 90.2%, respectively. Test-retest reliability analyses demonstrated good score reproducibility (ICC: HSSDD: 0.80-0.86; HSSQ: 0.73-0.82). Correlations between HSSDD and HSSQ scores and other PROs/ClinROs were generally consistent with predefined hypotheses, indicating good convergent validity. HSSDD and HSSQ scores discriminated between pre-defined subgroups, confirming known-groups validity. Sixteen-wk changes from baseline in HSSDD and HSSQ scores and anchors were moderately to strongly correlated (> 0.30), establishing responsiveness. Interpretation thresholds for both HSSDD and HSSQ were estimated.
HSSDD and HSSQ item scores demonstrated good psychometric performance in participants with moderate to severe HS. The clinically meaningful severity thresholds defined here could be used to assess treatment efficacy.
NCT04242446; NCT04242498.
化脓性汗腺炎(HS)是一种慢性炎症性疾病,其特征为疼痛性皮肤病变,对患者的身心健康产生负面影响。HS症状每日日记(HSSDD)和HS症状问卷(HSSQ)是患者报告结局(PRO)工具,用于记录患者对HS症状严重程度的感知。在此,我们报告了HSSDD和HSSQ的心理测量特性以及分数解释阈值。
分析了两项3期研究(BE HEARD I II)中中度至重度HS患者的汇总数据。使用组内相关系数(ICC)评估重测信度。在基线和第16周时,将HSSDD(N = 934)和HSSQ(N = 1007)与相关的PRO和临床医生报告结局(ClinRO)进行比较,评估收敛效度。评估已知组效度,比较使用PRO/ClinRO测量(HS严重程度的患者整体印象[PGI]、Hurley分期、国际HS严重程度评分系统)预先定义的参与者亚组之间的HSSDD和HSSQ分数。通过将HSSDD和HSSQ分数从基线到第16周的变化与PGI量表的变化进行相关性分析来评估反应性。使用基于锚点和分布的分析估计患者内部具有临床意义的改善阈值。使用受试者操作特征曲线分析估计症状/影响严重程度阈值。
在第16周时,HSSDD和HSSQ的完成率分别为70.1%和90.2%。重测信度分析显示分数具有良好的可重复性(ICC:HSSDD:0.80 - 0.86;HSSQ:0.73 - 0.82)。HSSDD和HSSQ分数与其他PRO/ClinRO之间的相关性通常与预定义的假设一致,表明具有良好的收敛效度。HSSDD和HSSQ分数在预定义的亚组之间存在差异,证实了已知组效度。HSSDD和HSSQ分数从基线到第16周的变化与锚点之间存在中度至高度相关性(> 0.30),确立了反应性。估计了HSSDD和HSSQ的解释阈值。
HSSDD和HSSQ项目分数在中度至重度HS患者中表现出良好的心理测量性能。此处定义的具有临床意义的严重程度阈值可用于评估治疗效果。
NCT04242446;NCT04242498。